ML348
Based on 12 publication(s) in Google Scholar
ML348 (GNF-Pf-1127) is a selective and reversible acyl-protein thioesterase 1 (APT1)/lysophospholipase 1 (LYPLA1) inhibitor with an IC50 of 210 nM, and barely inhibits LYPLA2.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 899713-86-1
- Formula: C18H17ClF3N3O3
- Molecular Weight:415.79
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Lipid Metabolism Compound Library
HY-L091
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) ML348
More- Adv Mater. 2021 Dec;33(49):e2103471. [Abstract]
- Nat Biomed Eng. 2019 Apr;3(4):306-317. [Abstract]
- Nat Commun. 2023 Oct 21;14(1):6682. [Abstract]
- Nat Commun. 2020 Sep 21;11(1):4765. [Abstract]
- Adv Sci (Weinh). 2025 Jul 11:e00971. [Abstract]
- Int J Biol Sci. 2025 Jun 9;21(9):3852-3866. [Abstract]
- EMBO J. 2025 May;44(9):2596-2619. [Abstract]
- Cell Rep. 2026 Jan 24;45(2):116910. [Abstract]
- Cell Oncol (Dordr). 2026 Apr 14;49(2):71. [Abstract]
- Mol Nutr Food Res. 2025 Sep;69(18):e70012. [Abstract]
- iScience. 2024 Sep 3;27(9):110880. [Abstract]
- J Virol. 2026 Jun 18:e0063826. [Abstract]
Customer Validation & Images
-
WB
-
IF
-
Cell Imaging/Staining
-
Flow Cytometry
-
Cell Imaging/Staining
All Phospholipase Isoforms
More
Biological Activity
IC 50: 210 nM (LYPLA1)
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Huh-7 | CC50 |
>100 μM
Compound: GNF-Pf-1127
|
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
|
[PMID: 18579783] |
ML348 (5 μM; 3 hours ) selectively inhibits LYPLA1 in cultured cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293T cells, murine T-cells
-
Concentration:5 µM
-
Incubation Time:3 hours
-
Result:Show potent, selective inhibition of LYPLA1.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL6 male mice (3-4 months)[1]
-
Dosage:50 mg/kg
-
Administration:Intraperitoneal injection; 3 hours
-
Result:Potent and selective inhibited LYPLA1 enzymes in heart, kidney and lung in vivo.
Chemical Information
-
CAS No. 899713-86-1
-
Appearance Solid
-
Molecular Weight 415.79
-
Formula C18H17ClF3N3O3
-
Color White to off-white
-
SMILES
O=C(NC1=CC(C(F)(F)F)=CC=C1Cl)CN2CCN(C(C3=CC=CO3)=O)CC2
-
Synonyms
GNF-Pf-1127
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Adv Mater
2021 Dec;33(49):e2103471. PMID: 34665481
ML348 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2021 Dec;33(49):e2103471. [Abstract]
ML348 (5 μM, 24 h) increased the infection efficiency of the pseudotype virus in ML348-pretreated cells.
ML348 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2021 Dec;33(49):e2103471. [Abstract]
ML348 (5 μM, 24 h) increased the infection efficiency of the pseudotype virus in ML348-pretreated cells.
ML348 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2021 Dec;33(49):e2103471. [Abstract]
ML348 (5 μM, 48 h) increased the infection efficiency of the pseudotype virus in HEK293T cells stably expressing ACE2 upon infection with SARS-CoV-2-GFP pseudovirus (MOI of 1).
-
Nat Biomed Eng
2019 Apr;3(4):306-317. PMID: 30952982 -
Nat Commun
Palmitoyltransferase DHHC9 and acyl protein thioesterase APT1 modulate renal fibrosis through regulating β-catenin palmitoylation. [Abstract]2023 Oct 21;14(1):6682. PMID: 37865665
ML348 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Oct 21;14(1):6682. [Abstract]
ML348 (4–16 μM, 12–36 h) decreased the abundance of β-catenin (including its active form) and Cyclin D1, and increased its phosphorylated form in PTCs.
ML348 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Oct 21;14(1):6682. [Abstract]
ML348 (intraperitoneal injection 3.2 mg/kg/day, 10 days) markedly attenuated interstitial matrix deposition and tubular atrophy in mice after UUO.
-
Nat Commun
2020 Sep 21;11(1):4765. PMID: 32958780 -
Adv Sci (Weinh)
Dysfunctional Decidual CD4+T Cells Induce Recurrent Pregnancy Loss via Palmitoylation-Dependent Tim-3 Lysosomal Sorting and Degradation. [Abstract]2025 Jul 11:e00971. PMID: 40642872 -
Int J Biol Sci
APT1-derived depalmitoylation of CD36 alleviates diabetes-induced lipotoxicity in podocytes. [Abstract]2025 Jun 9;21(9):3852-3866. PMID: 40607256 -
EMBO J
S-palmitoylation modulates ATG2-dependent non-vesicular lipid transport during starvation-induced autophagy. [Abstract]2025 May;44(9):2596-2619. PMID: 40128367 -
Cell Rep
2026 Jan 24;45(2):116910. PMID: 41581148 -
Cell Oncol (Dordr)
Integrative analysis and functional validation identified palmitoylated PHGDH as a therapeutic target for colon adenocarcinoma. [Abstract]2026 Apr 14;49(2):71. PMID: 41979705 -
Mol Nutr Food Res
Protocatechuic Acid Reduces Liver Fatty Acid Uptake in HFD-Fed Mice Associated With the Inhibition of DHHC5-Mediated CD36 Palmitoylation. [Abstract]2025 Sep;69(18):e70012. PMID: 40109131 -
iScience
mCAUSE: Prioritizing mitochondrial targets that alleviate pancreatic cancer cell phenotypes. [Abstract]2024 Sep 3;27(9):110880. PMID: 39310760 -
J Virol
Palmitoylation of CLDN12 regulated by ZDHHC7 and APT1/2 promotes hepatitis C virus entry. [Abstract]2026 Jun 18:e0063826. PMID: 42312836
Solvent & Solubility
DMSO : 25 mg/mL (60.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4051 mL | 12.0253 mL | 24.0506 mL | 60.1265 mL |
| 5 mM | 0.4810 mL | 2.4051 mL | 4.8101 mL | 12.0253 mL | |
| 10 mM | 0.2405 mL | 1.2025 mL | 2.4051 mL | 6.0127 mL | |
| 15 mM | 0.1603 mL | 0.8017 mL | 1.6034 mL | 4.0084 mL | |
| 20 mM | 0.1203 mL | 0.6013 mL | 1.2025 mL | 3.0063 mL | |
| 25 mM | 0.0962 mL | 0.4810 mL | 0.9620 mL | 2.4051 mL | |
| 30 mM | 0.0802 mL | 0.4008 mL | 0.8017 mL | 2.0042 mL | |
| 40 mM | 0.0601 mL | 0.3006 mL | 0.6013 mL | 1.5032 mL | |
| 50 mM | 0.0481 mL | 0.2405 mL | 0.4810 mL | 1.2025 mL | |
| 60 mM | 0.0401 mL | 0.2004 mL | 0.4008 mL | 1.0021 mL |
ML348 Related Classifications
HY-100736 Related Classifications
Powered by Bioz